Progressing PROTACS, Molecular Glues, & Emerging Proximity Therapeutics to the Clinic with Improved Safety & Drug Properties to Target Undruggables in Oncology & Beyond
The 6th TPD & Induced Proximity Summit Europe is the only European forum dedicated exclusively to proximity-based drug discovery. From PROTACs and molecular glues to stabilizers and extracellular degraders, this summit showcases the full spectrum of therapeutic innovation across oncology, neurodegeneration, immunology, and rare diseases. Held in London in March 2026, the event brings together more than 80 CxOs, directors, senior scientists and investors to accelerate proximity therapeutics from discovery to clinic.
Europe is experiencing a surge in strategic investment and innovation, including Sanofi’s acquisition of Blueprint Medicines for £7.2 billion and Merck’s £2.7 billion purchase of SpringWorks Therapeutics. As the region pivots toward non-oncology indications and novel mechanisms, drug developers face challenges in rational design, oral bioavailability, PK and PD modelling, and clinical translation. This summit addresses those challenges with insights from leading companies such as GSK, Abbvie, Amphista, Autotac Bio, PhoreMost, Laigo Bio, and Foghorn Therapeutics. Attendees will gain access to first-in-human data, biology-first strategies, and novel degradation platforms that are redefining the druggable proteome.
Whether you are advancing early discovery or preparing clinical candidates, this is your essential opportunity to connect with Europe's most innovative biopharma teams and stay ahead in the evolving induced proximity landscape
TPD & Induced Proximity Europe offers the opportunity for thought leaders to converge and exchange ideas on current best practices, future directions, and all other facets of discovering and developing degraders.
Kevin Wilson, Vice President, Head of Chemistry, Foghorn Therapeutics
An ideal space to connect, all at once, to diverse people working in so many complementary aspects in degradation.
Victor Guallar, ICREA Professor and Group Leader, Barcelona Supercomputing Center
The TPD Summits are renowned meetings in the TPD field which allows for optimal exchange of the latest insights and developments in the (bio)TPD field, also beyond PROTACs and Molecular Glues. Besides, the meeting offers excellent networking opportunities that is essential for a young biotech like ours.
Maureen Galmes-Spit, Vice President of Research, Laigo bio
Explore the Full Event Guide
- 25+ Expert Speakers from Leading Biopharma and Academia
- 15+ Data-Led Case Studies Showcasing Clinical Updates, Novel Ligases, and Glue Discovery Breakthroughs
- 8+ Hours of Networking Including Speed Networking, Poster Sessions, and Informal Collaboration
- 3 Deep-Dive Workshops on Antibody-Based Degraders, Non-Oncology Applications, and Glueable Target Identification
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover the latest breakthroughs in PROTACs, molecular glues, and proximity therapeutics through expert-led sessions and case studies.
Partner With Us
Connect with Europe's leading drug developers seeking discovery platforms, chemistry services, and translational support for TPD programs.
Join the TPD Community
Network with top scientists and biopharma innovators driving proximity-based drug development across oncology, CNS, and beyond.